This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Prostate cancer	Androgen receptor	<p><i>In vitro</i> studies identified six scaffolds that could lead to the development of new androgen receptor inhibitors to treat prostate cancer. Virtual screening and <i>in vitro</i> testing of a small molecule library identified six hits that bound a transcriptional activation site on the androgen receptor and inhibited the receptor at low micromolar IC₅₀ values. Ongoing work includes testing the hits and their analogs in prostate cancer cell lines, including drug-resistant lines.</p> <p>SciBX 4(33); doi:10.1038/scibx.2011.932 Published online Aug. 25, 2011</p>	Patented by The University of British Columbia; available for licensing and partnering	<p>Axerio-Cilies, P. <i>et al. J. Med. Chem.</i>; published online Aug. 16, 2011; doi:10.1021/jm200532b</p> <p>Contact: Artem Cherkasov, The University of British Columbia, Vancouver, British Columbia, Canada e-mail: artc@interchange.ubc.ca</p>